Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2022-03-29 Board/Management Inform…
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or dismissal of outside directors (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This specifically pertains to changes in the company's board of directors composition. According to the provided definitions, announcements regarding changes in the board of directors or senior management fall under the 'MANG' category.
2022-03-29 Korean
대표이사(대표집행임원)변경(안내공시)
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the change of a company's representative director (CEO). It explicitly lists the 'before' and 'after' status of the leadership, the reason for the change (term expiration), and the effective date. This falls directly under the definition of Board/Management Information (MANG).
2022-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/proper), key financial data (assets, liabilities, revenue, profit/loss) for both consolidated and separate financial statements, and identifies the external auditor. While it contains financial data, it is a standardized regulatory disclosure form announcing the receipt and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2021
2022-03-21 Korean
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for the 66th fiscal year (2021-01-01 to 2021-12-31). It contains comprehensive financial statements, management discussion and analysis, and corporate governance details, which are the standard components of an Annual Report (10-K equivalent in the Korean market). It is not an announcement of a report, but the report itself. FY 2021
2022-03-21 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for JW Pharmaceutical's 66th Annual General Meeting. It contains the meeting agenda, voting procedures, director activity reports, and management information. In the context of US-style filings, this is equivalent to a Proxy Statement (DEF 14A) as it provides shareholders with the necessary information to vote on board elections, financial statement approval, and other corporate governance matters.
2022-03-14 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to provide shareholders with information regarding upcoming general meetings, including agenda items like director appointments, financial statement approval, and remuneration limits. This document is specifically designed to solicit proxies for the Annual General Meeting (AGM). In the context of the provided categories, this aligns perfectly with 'Proxy Solicitation & Information Statement' (PSI).
2022-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.